期刊
NEUROTHERAPEUTICS
卷 5, 期 4, 页码 516-527出版社
SPRINGER
DOI: 10.1016/j.nurt.2008.08.002
关键词
amyotrophic lateral sclerosis; clinical trial; trial design; conduct; critical review
Tremendous advances in our understanding of pathogenesis of amyotrophic lateral sclerosis (ALS) have provided a rich pipeline of drugs for clinical trialists. At least 32 unique compounds have been tested. Nevertheless, riluzole is currently the only treatment that prolongs survival. We present a critical overview of past clinical trials, how therapies are selected for testing in people, challenges with ALS clinical trial design and conduct, and ways to best move forward.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据